Literature DB >> 2043345

Specific inhibition of ribonucleotide reductases by peptides corresponding to the C-terminal of their second subunit.

G Cosentino1, P Lavallée, S Rakhit, R Plante, Y Gaudette, C Lawetz, P W Whitehead, J S Duceppe, C Lépine-Frenette, N Dansereau.   

Abstract

Previous studies have shown that herpes virus ribonucleotide reductase can be inhibited by a synthetic nonapeptide whose sequence is identical to the C-terminal of the small subunit of the enzyme. This peptide is able to interfere with normal subunit association that takes place through the C-terminal of the small subunit. In this report, we illustrate that inhibition of ribonucleotide reductases by peptides corresponding to the C-terminal of subunit R2 is also observed for the enzyme isolated from Escherichia coli, hamster, and human cells. The nonapeptide corresponding to the bacterial C-terminal sequence was found to inhibit E. coli enzyme with an IC50 of 400 microM, while this peptide had no effect on mammalian ribonucleotide reductase. A corresponding synthetic peptide derived from the C-terminal of the small subunit of the human enzyme inhibited both human and hamster ribonucleotide reductases with IC50 values of 160 and 120 microM, respectively. However, this peptide had no inhibitory activity against the bacterial enzyme. Equivalent peptides derived from herpes virus ribonucleotide reductase had no effect on either the bacterial or mammalian enzymes. Thus, subunit association at the C-terminal of the small subunit appears to be a common feature of ribonucleotide reductases. In addition, the inhibitory phenomenon observed with peptides corresponding to the C-terminal appears not only to be universal, but also specific to the primary sequence of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043345     DOI: 10.1139/o91-011

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  5 in total

1.  Cloning and characterization of the R1 and R2 subunits of ribonucleotide reductase from Trypanosoma brucei.

Authors:  A Hofer; P P Schmidt; A Gräslund; L Thelander
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 2.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

3.  The structural basis for peptidomimetic inhibition of eukaryotic ribonucleotide reductase: a conformationally flexible pharmacophore.

Authors:  Hai Xu; James W Fairman; Sanath R Wijerathna; Nathan R Kreischer; John LaMacchia; Elizabeth Helmbrecht; Barry S Cooperman; Chris Dealwis
Journal:  J Med Chem       Date:  2008-07-09       Impact factor: 7.446

4.  Cloning, sequence determination, and regulation of the ribonucleotide reductase subunits from Plasmodium falciparum: a target for antimalarial therapy.

Authors:  H Rubin; J S Salem; L S Li; F D Yang; S Mama; Z M Wang; A Fisher; C S Hamann; B S Cooperman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

5.  Specific inhibition of herpes virus replication by receptor-mediated entry of an antiviral peptide linked to Escherichia coli enterotoxin B subunit.

Authors:  A Marcello; A Loregian; A Cross; H Marsden; T R Hirst; G Palù
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.